Cargando…
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Updated immunization strategies are needed to address multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim results from an ongoing, open-label phase 2/3 trial evaluating the safety and immunogenicity of the bivalent Coronavirus Disease 2019 (COVID-19...
Autores principales: | Chalkias, Spyros, Eder, Frank, Essink, Brandon, Khetan, Shishir, Nestorova, Biliana, Feng, Jing, Chen, Xing, Chang, Ying, Zhou, Honghong, Montefiori, David, Edwards, Darin K., Girard, Bethany, Pajon, Rolando, Dutko, Frank J., Leav, Brett, Walsh, Stephen R., Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671805/ https://www.ncbi.nlm.nih.gov/pubmed/36202997 http://dx.doi.org/10.1038/s41591-022-02031-7 |
Ejemplares similares
-
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
por: Chu, Laurence, et al.
Publicado: (2022) -
LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022) -
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)